Characterisation of CpG methylation in the upstream control region of mouse Nat2: Evidence for a gene-environment interaction in a polymorphic gene implicated in folate metabolism

Gene

Volumn 452, Issue 1, 2010, Pages 16-21

  Wakefield, Larissa ^a   Boukouvala, Sotiria ^b   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Arylamine N acetyltransferase; Cancer; DNA methylation; Epigenetic gene control; Folate; Mouse Nat2 gene

Indexed keywords

5 METHYLCYTOSINE; ARYLAMINE ACETYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FOLATE METABOLISM; GENE DELETION; GENE EXPRESSION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC REGULATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; VITAMIN SUPPLEMENTATION;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CPG ISLANDS; DIETARY SUPPLEMENTS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; ENVIRONMENT; FOLIC ACID; GENE DELETION; HUMANS; MICE; MOLECULAR SEQUENCE DATA; ORGAN SPECIFICITY; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID;

MURINAE; MUS;

EID: 74549182112     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2009.12.002     Document Type: Article

References (44)

1. Adam P.J., et al. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol. Cancer Res. 2003, 1:826-835.
2. Barker D.F., et al. Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet. Genomics 2006, 16:515-525.
3. Bieche I., Girault I., Urbain E., Tozlu S., Lidereau R. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res. 2004, 6:R252-263.
4. Boukouvala S., Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab. Rev. 2005, 37:511-564.
5. Boukouvala S., Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterization of alternative transcripts. Basic Clin. Pharmacol. Toxicol. 2005, 96:343-351.
6. Boukouvala S., Price N., Sim E. Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. Pharmacogenetics 2002, 12:385-394.
7. Boukouvala S., Price N., Plant K.E., Sim E. Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice. Biochem. J. 2003, 375:593-602.
8. Butcher N.J., Arulpragasam A., Goh H.L., Davey T., Minchin R.F. Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities. Biochem. J. 2005, 387:119-127.
9. Butcher N.J., Tetlow N.L., Cheung C., Broadhurst G.M., Minchin R.F. Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res. 2007, 67:85-92.
10. Butcher N.J., Tiang J., Minchin R.F. Regulation of arylamine N-acetyltransferases. Curr. Drug Metab. 2008, 9:498-504.
11. Cornish V.A., et al. Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics J. 2003, 3:169-177.
12. Curtin K., et al. Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis 2007, 28:1672-1679.
13. Dolinoy D.C., Huang D., Jirtle R.L. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13056-13061.
14. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr. Top. Microbiol. Immunol. 2006, 310:251-274.
15. Erickson R.P., et al. Confirmation of the role of N-acetyltransferase 2 in teratogen-induced cleft palate using transgenics and knockouts. Mol. Reprod. Dev. 2008, 75:1071-1076.
16. Estrada-Rodgers L., Levy G.N., Weber W.W. Characterization of a hormone response element in the mouse N-acetyltransferase 2 (Nat2*) promoter. Gene Expr. 1998, 7:13-24.
17. Fakis G., Boukouvala S., Buckle V., Payton M., Denning C., Sim E. Chromosomal localisation and mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: identification of a novel upstream noncoding exon for murine Nat2. Cytogenet. Cell Genet. 2000, 90:134-138.
18. Hirsch S., et al. Methylation status in healthy subjects with normal and high serum folate concentration. Nutrition 2008, 24:1103-1109.
19. Husain A., Barker D.F., States J.C., Doll M.A., Hein D.W. Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 2004, 14:397-406.
20. Husain A., Zhang X., Doll M.A., States J.C., Barker D.F., Hein D.W. Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. Drug Metab. Dispos. 2007, 35:1649-1656.
21. Kawamura A., et al. Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1. Biochem. Pharmacol. 2008, 75:1550-1560.
22. Kim S.J., et al. Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. Oncol. Rep. 2008, 19:663-668.
23. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
24. Laird P.W. Cancer epigenetics. Hum. Mol. Genet. 2005, 14:R65-76.
25. Larsson S.C., Giovannucci E., Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006, 131:1271-1283.
26. Li L.C., Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18:1427-1431.
27. Loehle J.A., et al. N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice. J. Pharmacol. Exp. Ther. 2006, 319:724-728.
28. Marchal C., et al. Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer. Eur. J. Surg. Oncol. 2008, 34:805-810.
29. Minchin R.F. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem. J. 1995, 307:1-3.
30. Minchin R.F., Hanna P.E., Dupret J.M., Wagner C.R., Rodrigues-Lima F., Butcher N.J. Molecules in focus: arylamine N-acetyltransferase I. Int. J. Biochem. Cell Biol. 2007, 39:1999-2005.
31. Payton M., Smelt V., Upton A., Sim E. A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. Biochem. Pharmacol. 1999, 58:779-785.
32. Robien K., Boynton A., Ulrich C.M. Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 2005, 6:673-689.
33. Shields D.C., et al. The "thermolabile" variant of methylenetetrahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am. J. Hum. Genet. 1999, 64:1045-1055.
34. Sim E., Walters K., Boukouvala S. Arylamine N-acetyltransferases: from structure to function. Drug Metab. Rev. 2008, 40:479-510.
35. Sim E., Westwood I., Fullam E. Arylamine N-acetyltransferases. Exp. Opin. Drug Metab. Toxicol. 2007, 3:169-184.
36. Smelt V.A., et al. Expression of arylamine N-acetyltransferases in pre-term placentas and in human preimplantation embryos. Hum. Mol. Genet. 2000, 9:1101-1107.
37. Song J., Medline A., Mason J.B., Gallinger S., Kim Y.I. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res. 2000, 60:5434-5440.
38. Srour N., Reymond M.A., Steinert R. Lost in translation? A systematic database of gene expression in breast cancer. Pathobiology 2008, 75:112-118.
39. Suzuki T., et al. One-carbon metabolism-related gene polymorphisms and risk of breast cancer. Carcinogenesis 2008, 29:356-362.
40. Upton A., et al. Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancy. Biochim. Biophys. Acta 2000, 1524:143-148.
41. Vucic E.A., Brown C.J., Lam W.L. Epigenetics of cancer progression. Pharmacogenomics 2008, 9:215-234.
42. Wakefield L., Cornish V., Long H., Griffiths W.J., Sim E. Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism. Biochem. Biophys. Res. Commun. 2007, 364:556-560.
43. Wakefield L., et al. Mouse arylamine N-acetyltransferase 2 (Nat2) expression during embryogenesis: a potential marker for the developing neuroendocrine system. Biomarkers 2008, 13:106-118.
44. Ward A., Summers M.J., Sim E. Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem. Pharmacol. 1995, 49:1759-1767.